Almirall

Almirall - Pharmaceutical company committed to dermatology, pain and chronic pathologies

Founded in Barcelona in 1943, Almirall is an international pharmaceutical company specializing in the treatment of dermatological pathologies, chronic inflammatory conditions, gastrointestinal disorders and neurological pain. Present in over 10 countries, the group develops, manufactures and markets innovative therapeutic solutions, based on over 80 years' expertise in pharmaceutical research and development.

Today, Almirall is recognized for its major advances in the treatment of skin diseases such as psoriasis, actinic keratosis andeczema, as well as for its drugs targeting migraine, constipation and certain respiratory and neurological diseases . Its positioning is based on scientific excellence, continuous innovation and a deep commitment to unmet therapeutic needs.

Scientific development supported by high-level partnerships

Almirall actively collaborates with numerous public and private research centers worldwide. Our partners include :

• The Higher Center for Scientific Investigations (Spain)
• Barcelona Biomedical Investigation Centre
• Imperial College London
• The National Institute of Health (USA)
  

Almirall also participates in several European programs, such as theInnovative Medicines Initiative. These strategic collaborations feed the laboratory 's R&Dactivity, enabling the development of safe, effective and clinically validated medicines, thanks to rigorous testing and total transparency of published results.

A history rooted in family pharmacy and looking to the future

Milestones in Almirall's development include :

• 1979: launch of the gastroprokinetic cleboprida
• 1985: launch of piketoprofen, a topical anti-inflammatory agent
• 1990-1992: development ofebastine (antihistamine) andaceclofenac(NSAID)
• 2000: FDA approval ofAlmogran (almotriptan), an innovative migraine treatment
• 2013-2016: acquisitions of Aqua Pharmaceuticals, Poli Group and Themigen LLC
  

In 2014, Almirall transfers its respiratory franchise to AstraZeneca in order to focus fully on its core expertise: dermatology.

Core therapeutic areas

1. Medical dermatology

Dermatology is one of Almirall's major areas of focus, with a range of innovative medicines designed to treat chronic and inflammatory skin diseases:

• Psoriasis: topical or systemic treatments to limit inflammatory flare-ups and restore the skin barrier
• Actinic keratosis: Solaraze, a gel based on diclofenac sodium, is indicated in the treatment of these precancerous lesions induced by prolonged exposure to the sun
• Eczema and atopic dermatitis: local anti-inflammatory solutions for sensitive skin
  

2. Neurological pain and migraine

• Almogran:almotriptan-based medication, indicated for the acute treatment of migraine with or without aura. This latest-generation triptan acts by inhibiting the dilation of intracranial vessels and reducing the transmission of pain signals.
  

3. Gastrointestinal disorders

• Cebutid: cinitapride-based prokinetic drug, indicated for digestive motility disorders (dyspepsia, reflux, slow digestion).
• Spagulax: psyllium-based ballast laxative (Ispaghul), used for chronic constipation. This product contains mucilage which retains water, increasing stool volume and gently stimulating intestinal transit.
  

4. Female facial hirsutism

• Vaniqa: aneflornithine-based cream, indicated for slowing facial hair regrowth in women. It acts by blocking the enzyme responsible for hair proliferation.
  

Complementary flagship products and ongoing innovation

In addition to dermatology, Almirall develops products in the following fields:

• Respiratory: treatments forasthma and COPD, developed prior to the sale of the franchise in 2014
• Advanced gastroenterology: development of solutions for Crohn's disease, ulcerative colitis and functional intestinal syndromes
• Neurology: ongoing programs in the treatment of multiple sclerosis and Parkinson's disease
• Immunology: research into drugs targeting the immune system to treat rheumatoid arthritis or lupus
  

Pharmaceutical quality and ethical commitment

All drugs developed by Almirall are subject to strict quality standards, including Good Manufacturing Practices (GMP), rigorous monitoring of clinical trials, and transparent publication ofscientific data for prescribers and patients.

The laboratory is committed to bringing to market only products that have demonstrated real therapeutic efficacy, validated by national and international health authorities.

Almirall, science, rigor and innovation in the service of patient health

With over 80 years of history, a presence on several continents and a specialization in dermatology and specialized medicine, Almirall is positioned as a laboratory focused on the future of therapeutics. Its products are designed to respond effectively to specific medical needs, while guaranteeing safety, accessibility and constant innovation.

Whether treating skin conditions, neurological pain, digestive disorders or chronic ailments, Almirall medicines provide concrete clinical answers, backed by a solid scientific base and a responsible development policy.